Plain-English translation of NCT06606808 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis (UC) research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Researchers are studying risankizumab-800CW, a version of a medication used to treat inflammatory bowel disease that has been labeled with a special fluorescent dye. This dye allows doctors to see exactly where and how well the medication is reaching inflamed areas of the gut. The study will test different doses of this labeled medication and use imaging to track how it works in patients with Crohn's disease or ulcerative colitis.
Many patients don't respond well to this type of medication, but doctors currently have no way to predict who will benefit or to see how the treatment is actually working in the gut. This trial aims to use fluorescent imaging to visualize the medication in action, which could help predict treatment success and improve how doctors care for inflammatory bowel disease patients.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the labeled medication in one of three doses, then undergo a fluorescence imaging procedure to visualize how the medication concentrates in your inflamed bowel tissue. If you're already on this medication for at least 14 weeks, you may be eligible for a second part of the study where you receive the optimized dose and imaging. All imaging will happen during a scheduled endoscopy procedure.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Netherlands